The U.S. Food and Drug Administration GLO Skin Creamnotified the public in early 2008 that Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) had been in a few instances, related to feasible destructive reactions, which include respiration failure and loss of life. Some of these unfavorable reactions appeared to be related to the spread of the toxin to areas.